within Pharmacolibrary.Drugs.ATC.G;

model G03CA01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.45,
    Cl             = 0.2708333333333333,
    adminDuration  = 600,
    adminMass      = 2.9999999999999997e-05,
    adminCount     = 1,
    Vd             = 0.005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.01155,
    Tlag           = 1800
  );

  annotation(Documentation(
    info ="<html><body><p>Ethinylestradiol is a synthetic derivative of the natural estrogen estradiol. It is primarily used as an oral contraceptive, either alone or in combination with progestins, for the prevention of pregnancy. It is approved for clinical use and is a common component of combined oral contraceptive pills.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult females after a single oral dose.</p><h4>References</h4><ol><li><p>Moreira de Brito, C, et al., &amp; Cercato, C (2021). Pharmacokinetics of oral levonorgestrel and ethinylestradiol in women after Roux-en-Y gastric bypass surgery. <i>Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery</i> 17(4) 673–681. DOI:<a href=&quot;https://doi.org/10.1016/j.soard.2020.12.007&quot;>10.1016/j.soard.2020.12.007</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33547015/&quot;>https://pubmed.ncbi.nlm.nih.gov/33547015</a></p></li><li><p>Jordy, AB, et al., &amp; Bækdal, TA (2021). Effect of Oral Semaglutide on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women and Furosemide and Rosuvastatin in Healthy Subjects. <i>Clinical pharmacokinetics</i> 60(9) 1171–1185. DOI:<a href=&quot;https://doi.org/10.1007/s40262-020-00976-x&quot;>10.1007/s40262-020-00976-x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33782832/&quot;>https://pubmed.ncbi.nlm.nih.gov/33782832</a></p></li><li><p>Battipaglia, C, et al., &amp; Grandi, G (2023). Combined oral contraceptive with estetrol plus drospirenone: from pharmacokinetics to clinical applications. <i>Expert opinion on drug metabolism &amp; toxicology</i> 19(12) 871–879. DOI:<a href=&quot;https://doi.org/10.1080/17425255.2023.2279752&quot;>10.1080/17425255.2023.2279752</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37942662/&quot;>https://pubmed.ncbi.nlm.nih.gov/37942662</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end G03CA01;
